Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: Identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma
✍ Scribed by Ali Mohamed Ali Eldib; Toshiro Ono; Michihide Shimono; Miho Kaneko; Kazuhiko Nakagawa; Ryo Tanaka; Yuji Noguchi; Eiichi Nakayama
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- French
- Weight
- 170 KB
- Volume
- 108
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
By serologic identification of antigens by recombinant expression cloning (SEREX) analysis using an autologous lung adenocarcinoma cell line, OU‐LU‐6, as a cDNA library source, we demonstrated that XAGE‐1 was the dominant antigen recognized by serum from a patient. By immunoscreening, we obtained 38 positive cDNA clones consisting of 16 genes designated as OY‐LC‐1 to ‐OY‐LC‐16. OY‐LC‐1, represented by 18 clones, was identical to XAGE‐1. OY‐LC‐2 to ‐16, represented by either a single or 2 clones, were identical to known genes shown to be ubiquitously expressed in various normal tissues. RT‐PCR analysis showed that of 4 XAGE‐1 transcripts—XAGE‐1a, b, c and d—XAGE‐1b was expressed in OU‐LU‐6 dominantly. Furthermore, XAGE‐1b mRNA was expressed in 4 of 10 lung cancer tissues, whereas no expression was observed in normal tissues. Of 4 XAGE‐1b mRNA positive cancer tissues, 3 were adenocarcinoma and one was poorly differentiated squamous cell carcinoma. Of 32 sera from lung cancer patients, 8 sera were reactive with the XAGE‐1b product. Those 8 sera were from patients with adenocarcinoma. These findings indicated strong immunogenicity of XAGE‐1b in lung adenocarcinoma and suggested its potential use as a target for vaccine‐based immunotherapies. © 2003 Wiley‐Liss, Inc.